Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Labels

March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info: https://youtu.be/811v7RLXP9M
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country
MEBO TMAU TESTING DISCONTINUED
(2012-2017)

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
rareconnect.org TMAU

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

https://www.meboblog.com/2023/01/denver-tmau-test-survey-tbc-who-it-is.html

Friday, November 12, 2010

Chat with PTC representative about ataluren

We have had our chat with a PTC representative about ataluren and how the TMAU community could be best prepared to promote research into its use for TMAU cases with nonsense mutations. Nothing concrete came out of the dialogue, although hopefully we have made our case known to PTC at least, and the discussion itself was convivial. The representative was from the Customer Relations Department of the Company.


Here is a summary of the points discussed :

The representative pointed out that ataluren would only be potentially beneficial to those with genetic disorders caused by nonsense mutations. Nonsense mutations usually make up a small percentage of the cause for most genetic disorders.

While PTC is conducting some research studies in-house, it's unlikely TMAU would be added to their in-house list of trials in the forseeable future. It was suggested that our best prospect of getting an ataluren trial for TMAU would be to find a researcher externally, and possibly to lobby the NIH or FDA or other sources of funding.

Ataluren has been trialled in a large study for muscular dystrophy. The original results (mainly based on a '6 minute walk' to look for improvement) were not significant, but other data since seem to have shown improvement. It has been and is now being trialled in a number of disorders. Curiously it seemed to work better at smaller dosages, though this is not an uncommon trend.


The PTC Representative was informed of TMAU and is aware of the MEBO Research website. They pointed out that patient advocacy groups can have important pivotal roles in research, and their muscular dystrophy website was popinted out as a good example of a patient advocacy group acting as a hub and collating data. This is generally how MEBO Research sees it's future role as well. The rep was informed of the TMAU Foundation in New York, and was grateful for this information.

PTC is hoping that if all goes well ataluren will be approved by 2011, though of course this is subject to circumstances.

Overall it was a nice informal chat, and TMAU is now on their radar at least.

0 comments:

Post a Comment